Inovio Pharmaceuticals Tumbles After Roche Deal Falls Apart On Prostate Cancer Vaccine Deal

Dendreon files for Chapter 11 bankruptcy after disappointing sales for Provenge

The raised outlook reflects the continued strong performance of Vimizim and updated expectations. The market responded positively today.

Adcetris is already approved in more than 45 countries for the treatment of relapsed Hodgkin lymphoma and sALCL; now, new positive data as a consolidation therapy post-stem cell transplant.

Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC).

The Chart of the day belongs to Medivation. I found the stock by sorting the All Time New High list for new high frequency in the last month, then used the Flipchart feature to review the charts. Since the Trend Spotter signaled a buy on 7/23 the stock has gained 24.49%.